### Supplementary Table 2: Association of ROBO1 expression with clinicopathological features of CCA.

| Clinicopathological features | ROBO1 expression | P value | χ² |
|------------------------------|------------------|---------|----|
|                              | downregulated    | upregulated |     |
| All cases                    | 121 (63.7%)      | 69 (36.3%) | 0.006 | 7.578 |
| Gender                       |                  |         |     |
| Male                         | 84 (69.4%)       | 34 (49.3%) |       |      |
| Female                       | 37 (30.6%)       | 35 (50.7%) |       |      |
| Age                          |                  |         |     |
| ≤60                          | 62 (51.2%)       | 36 (52.2%) | 0.901 | 0.015 |
| >60                          | 59 (48.8%)       | 33 (47.8%) |       |      |
| CA199 (U/L)                  |                  |         |     |
| ≤37                          | 11 (9.1%)        | 10 (14.5%) | 0.087 | 2.929 |
| >37                          | 52 (43.0%)       | 20 (29.0%) |       |      |
| CEA (ng/ml)                  |                  |         |     |
| ≤5                           | 41 (33.9%)       | 18 (26.1%) | 0.566 | 0.330 |
| >5                           | 21 (17.4%)       | 12 (17.4%) |       |      |
| AFP (ng/ml)                  |                  |         |     |
| ≤20                          | 69 (57.0%)       | 34 (49.3%) | 0.746 | 0.105 |
| >20                          | 3 (2.5%)         | 2 (2.9%) |       |      |
| Diameter (cm)                |                  |         |     |
| ≤5                           | 73 (60.3%)       | 36 (52.2%) | 0.316 | 1.006 |
| >5                           | 30 (24.8%)       | 21 (30.4%) |       |      |
| Tumor No.                    |                  |         |     |
| 1                            | 64 (52.9%)       | 34 (49.3%) | 0.578 | 0.310 |
| ≥2                           | 6 (5.0%)         | 2 (2.9%) |       |      |
| Location                     |                  |         |     |
| Intrahepatic                 | 57 (47.1%)       | 42 (60.9%) | 0.068 | 3.335 |
| Perihilar                    | 64 (52.9%)       | 27 (39.1%) |       |      |
| Histological grade           |                  |         |     |
| I/I-II/II                    | 52 (43.0%)       | 37 (53.6%) | 0.195 | 1.681 |
| II-III/III                   | 61 (50.4%)       | 29 (42.0%) |       |      |
| Nerve invasion               |                  |         |     |
| Absent                       | 49 (40.5%)       | 32 (46.4%) | 0.273 | 1.201 |
| Present                      | 59 (48.8%)       | 27 (39.1%) |       |      |
| Tumor thrombus               |                  |         |     |
| Absent                       | 96 (79.3%)       | 58 (84.1%) | 0.653 | 0.202 |
| Present                      | 20 (16.5%)       | 10 (8.3%) |       |      |
| T stage                      |                  |         |     |
| Tis-T1                       | 38 (31.4%)       | 31 (44.9%) | 0.069 | 3.312 |
| T2-T4                        | 80 (66.1%)       | 37 (53.6%) |       |      |
| N stage                      |                  |         |     |
| N0                           | 84 (69.4%)       | 54 (78.3%) | 0.187 | 1.742 |
| N1, N2                       | 35 (28.9%)       | 14 (20.3%) |       |      |
| M stage                      |                  |         |     |
| M0                           | 117 (96.7%)      | 68 (98.6%) | 0.447 | 0.579 |
| M1                           | 1 (0.8%)         | 0 (0.0%) |       |      |
| Clinical stage               |                  |         |     |
| I/II                         | 62 (51.2%)       | 45 (65.2%) | 0.061 | 3.502 |
| III/IV                       | 57 (47.1%)       | 23 (33.3%) |       |      |
| Surgical margin              |                  |         |     |
| R0                           | 102 (84.3%)      | 60 (87.0%) | 0.711 | 0.137 |
| R1, R2                       | 18 (14.9%)       | 9 (13.0%) |       |      |